Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kiran Narsinh

Gastroenterology San Pablo, CA Medical Doctor

NPI 1730316977 CMS profile 1153243

2089 Vale Rd, Suite 33, San Pablo, CA 94806

Open in the dashboard

General payments

$1,823

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,483 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Kiran Narsinh of San Pablo, CA is reported in the CMS Open Payments database as having received $1,823 across 80 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,483 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 45th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $618 26
2024 General $461 19
2023 General $315 14
2022 General $108 5
2021 General $28 2
2020 General $22 1
2019 General $271 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kiran Narsinh
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Kiran Narsinh were reported at $618. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Kiran Narsinh Gastroenterology median Middle half National median
2019 $271 $417 $126–$1,100 $163
2020 $22 $224 $74–$624 $114
2021 $28 $352 $106–$1,054 $132
2022 $108 $448 $129–$1,270 $149
2023 $315 $533 $150–$1,390 $160
2024 $461 $605 $160–$1,606 $164
2025 $618 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $498 22 payments
  2. Janssen Biotech, Inc. $312 13 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $263 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $122 5 payments
  5. Gilead Sciences, Inc. $77 4 payments
  6. Merck Sharp & Dohme Corporation $66 3 payments
  7. Lilly USA, LLC $65 2 payments
  8. QOL Medical, LLC $63 3 payments
  9. Aimmune Therapeutics, Inc. $63 2 payments
  10. Celltrion USA Inc. $49 2 payments
  11. Other $246 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,793 78 payments
  2. Education $30 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $340 14 payments
  2. XIFAXAN $282 12 payments
  3. TREMFYA $223 10 payments
  4. SKYRIZI Immunology $176 7 payments
  5. SKYRIZI Immunology $144 6 payments
  6. ENTYVIO $107 4 payments
  7. HUMIRA $95 4 payments
  8. STELARA $89 3 payments
  9. DIFICID $66 3 payments
  10. OMVOH $65 2 payments
  11. Other $607 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

326

Median for Gastroenterology: 569

Drug cost

$91,795

Median for Gastroenterology: $104,976

Branded share of claims

37.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 11 $39,550
Linzess Linaclotide Brand 15 $22,341
Mesalamine Generic 23 $18,217
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 41 $6,640
Pantoprazole Sodium Generic 71 $1,264
Azathioprine Generic 14 $1,080
Omeprazole Generic 86 $938
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 12 $718
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 20 $510
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $324

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$93,378

Medicare's payments for the services billed

Medicare patients

187

Average age 72

Services billed

1,303

133 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 43%
Arthritis 37%
Depression 25%
Chronic kidney disease 24%
Ischemic heart disease 19%
COPD 19%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DIFICID
  • Merck Sharp & Dohme Corporation $66
$66 — —
TREMFYA
  • Janssen Biotech, Inc. $62
$62 — —
STELARA
  • Janssen Biotech, Inc. $51
$51 — —
Sucraid
  • QOL Medical, LLC $42
$42 — —
RINVOQ
  • AbbVie, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record